With shares of Caribou Biosciences (NASDAQ: CRBU) up by 51% in the past 30 days, there's more than one reason why you might want to consider a purchase for yourself. Between its recent release of some ...
Caribou's most advanced program is called CB-010, and it's being investigated in a phase 1 clinical trial for treating relapsed or refractory B-cell non-Hodgkin's lymphoma. On July 13, the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results